Post by
Duster340 on Jan 03, 2024 10:15am
a possible theory
remember it is always the shareholder that gets screwed. it is all about timing for the company dan himself has said before it is all about the timing. i think another cash raise is coming that will be sometime after the 30 day exercise period ends on feb/15 and before the P2 results in Q3. the reason is in case of failure of otena for the 2nd time, the company will need to be cashed up to survive and continue on with there next in line ibd drug and management will be able to collect a pay cheque for another few years. that will be the #1 priority. more dilution coming think about it this is the way it has to play out, if they do not do a financing deal in the next few months while the stock price is high, no one will finance them if the drug fails and the stock drops to a dime. they have no choice they can not take the risk and hope the drug is successful. could be why they are padding there bottom line with the warrants deal and the higher stock price so they can secure a good financing deal.
my opinion only
glta